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Abstract
Lifelong exercise is associated with regulation of skeletal mass and function,
reductions in frailty, and successful aging. Yet, the influence of exercise on
myostatin and myostatin-interacting factors is relatively under examined in
older males. Therefore, we investigated whether serum total myostatin, free
myostatin, follistatin, and growth and differentiation factor 11 (GDF11) were
altered following high-intensity interval training (HIIT) in a group of 13 life-
long sedentary (SED; 64 [6] years) and 11 lifelong exercising (LEX; 62 [6]
years) older males. SED follistatin was moderately greater than LEX pre-HIIT
(Cohen’s d = 0.66), and was largely greater post-HIIT (Cohen’s d = 1.22).
The HIIT-induced increase in follistatin was large in SED (Cohen’s d = 0.82)
and absent in LEX (Cohen’s d = 0.03). GDF11 was higher in LEX pre-HIIT
(Cohen’s d = 0.49) and post-HIIT (Cohen’s d = 0.63) compared to SED.
HIIT resulted in no change to GDF11 in LEX or SED (Cohen’s d = 0.00–
0.03). Peak power output and GDF11 were correlated (r = 0.603), indepen-
dent of grouping. Differences in GDF11 with lifelong exercise training, paired
with the correlation between GDF11 and peak power output, suggested that
GDF11 may be a relevant myostatin-interacting peptide to successful aging in
humans, and strategies to maintain this need to be further explored.
Introduction
Myostatin (originally growth and differentiation factor 8
[GDF8]) is a procatabolic, antianabolic peptide hormone
that is a central regulator of skeletal muscle mass (Elliott
et al. 2012). Secreted by the skeletal muscle, myostatin is
found in an active unbound (free) form, or bound to its
own propeptide, or separate peptides such as follistatin,
or follistatin-related gene (FLRG; Hill et al. 2002; Amthor
et al. 2004; Gilson et al. 2009), each inhibiting its
biological function. Myostatin has both paracrine and
endocrine effects (Zimmers et al. 2002), although it is the
endocrine function which appears key for regulation of
muscle mass, due to an observed inverse correlation with
muscle mass in humans (Gonzalez-Cadavid et al. 1998).
Moreover, inhibition of this endocrine function results in
muscle hypertrophy in mice (Whittemore et al. 2003).
Aging is associated with a progressive loss of muscle
mass and associated function (Metter et al. 2002). The rate
of loss of muscle mass and function with aging is noted to
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differ between individuals, which gave rise to “usual” and
“successful” aging hypothesis (Rowe and Kahn 1987). A
more recent definition of successful aging being “optimisa-
tion of life expectancy while minimising physical and men-
tal deterioration and disability” (Bowling and Dieppe
2005), a trait that is often seen in lifelong masters athletes
(Pollock et al. 2015). While the role of myostatin in regula-
tion of muscle mass is well described, there are few data
and no prospective studies to contextualize the influence
of myostatin within the “cycle of frailty” that precedes sar-
copenia. From the few cross-sectional studies, one
observed ~50% higher plasma myostatin in older sedentary
(SED; ~63–75 years of age) compared with younger
healthy (~20–35 years of age) men (Yarasheski et al. 2002).
However, this was not replicated in a study of men aged
~22, ~69, and ~76 years of age, regardless of sarcopenic
severity (Ratkevicius et al. 2011). Recently, we have
observed an inverse association between age and plasma
myostatin in a large group (n = 88) of healthy individuals
aged 18–72 years of age (Elliott et al. 2016). Considering
the current incomplete understanding concerning the role
of myostatin and myostatin-interacting peptides in the
aging process, the pool of evidence needs to be extended.
Growth and differentiation factor 11 (GDF11) is a pep-
tide with similar sequence homology as myostatin, and it
is possible that both peptides share similar signaling path-
ways and biological influence within the skeletal muscle.
Unlike myostatin, however, the expression of GDF11 is
not limited to skeletal muscle tissue (Lee and McPherron
1999; Walker et al. 2016). There also appears to be an
indicated role for GDF11 in the aging process; higher cir-
culating GDF11 in middle-aged mice has been positively
associated with longevity and exposure of aged mice to a
youthful systemic environment led to restoration of skele-
tal muscle and hepatic cellular function (Zhou et al.
2016). Similarly, the aging muscle phenotype is partially
offset by provision of recombinant GDF11, as demon-
strated by increased grip strength and running endurance
in mice (Sinha et al. 2014).
While it remains to be seen whether these findings can
be consistently replicated, or indeed translated to the
human model of aging, only a small number of studies
that have examined the effects of exercise training on
serum myostatin and associated mRNA expression, while
GDF11 remains unexamined in the human exercise
model. Indeed, 2–3 months’ resistance training in healthy
young individuals resulted in increased muscle mass and
decreased muscle mRNA and serum myostatin (Roth
et al. 2003; Walker et al. 2004). To the best of these
authors’ knowledge, no reports on the effect of exercise
(in any form) on GDF11 expression currently exist.
Recently, high-intensity interval training (HIIT) has
received much attention due to its physiological and
sociological benefits. Indeed, HIIT is noted to be more
enjoyable than traditional, continuous training (Thum
et al. 2017), has higher compliance in patient populations
than continuous training (Shiraev and Barclay 2012), and
is noted to have equal or improved clinical outcomes in a
number of aging-related cardiovascular or metabolic dis-
orders (Ramos et al. 2015; Cassidy et al. 2016). While not
optimized for muscle hypertrophy, HIIT improves
myofibrillar protein synthesis (Bell et al. 2015), muscle
power (Sculthorpe et al. 2017), and fat-free mass (FFM)
(Herbert et al. 2017) in older males.
Therefore, in order to progress our understanding of
the biological relationship between myostatin and myo-
statin-interacting peptides with aging and exercise, the
aim of this preliminary study was twofold: (1) to compare
resting levels of plasma myostatin and myostatin-interact-
ing peptides between lifelong SED and a positive control
group of lifelong exercising (LEX) aging men, and (2) to
examine the influence of 6 weeks’ HIIT on plasma myo-
statin and myostatin-interacting peptides in SED and
LEX. We hypothesized that on enrollment to the study
SED would exhibit higher myostatin, follistatin, free myo-
statin, and lower GDF11. We further hypothesized that
6 weeks’ HIIT would decrease plasma myostatin, follis-
tatin, and free myostatin in SED, and increase GDF11.
Methods
Participants
Participants provided written informed consent prior to
enrollment to a larger study (Knowles et al. 2015; Hayes
et al. 2017; Herbert et al. 2017), which was approved by
the University of the West of Scotland Ethics Committee
(Reference: UEC16_042012/Herbert). Participants were
familiarized with experimental procedures and approval
to exercise was given by their general practitioner. Subse-
quently, a subgroup of 24 males was analyzed for this
pilot investigation. Thirteen males participated in the
SED group, while 11 males participated in the LEX group
(Table 1). Participants in the SED group did not take
part in any formal exercise training and had not done so
for >30 years. The LEX group were active exercisers and
had been so for the previous >30 years. They consisted
primarily of current masters competitors in sports includ-
ing water polo, triathlon, sprint cycling, road cycling, and
distance running. For 6 weeks prior to commencing HIIT
training, LEX recorded their normal weekly exercise,
which included type, frequency, intensity (recorded by
heart rate telemetry), and duration of training. Time
spent in low to medium intensity (<65% heart rate
reserve [HRR]), and high-intensity (>65% HRR) training
totaled 214  131 and 67  52 min/week, respectively.
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Group selection was affirmed by differences in aerobic
conditioning (peak oxygen uptake; VO2peak) between
groups (Table 1). Participants were tested pre- and post-
HIIT at the same time of day, 7 weeks apart. Order of
measurements was blood sampling, body composition,
peak power assessment, and determination of VO2peak.
Blood draws and analysis
Participants arrived at the exercise physiology laboratory
between 0700 and 0900 h, following an overnight fast and
having abstained from strenuous exercise for a minimum
of 48 h. Participants were reminded to maintain stan-
dardized conditions prior to each assessment point which
included arriving in a hydrated state having abstained
from caffeine and alcohol consumption for 36 h. Follow-
ing 20 min supine rest, blood was sampled from the non-
dominant arm using the standard venipuncture method
into sterile serum separator vacutainer tubes (Becton
Dickinson, Rutherford, NJ) that were kept at room tem-
perature in the dark, for 30 min, to allow for clotting,
after which samples were centrifuged at 1100g at 4°C for
15 min. Serum was then extracted, aliquoted, and stored
at 80°C until subsequent analysis. Blood samples were
collected at the same time of day for each participant to
control for biological variation and minimize interpartici-
pant analytical variation.
Concentrations of serum myostatin protein (both total
and free fractions) were quantified by enzyme-linked
immunosorbent assay (ELISA; DGDF80; R&D Systems,
UK). Briefly, aliquots of serum were brought to room
temperature, before 100 lL of plasma was diluted with
1:4 diluent buffer (free myostatin) or activated with
50 lL HCl (6 mol, 10 min at room temperature)
for removal of myostatin binding proteins, before
neutralization (50 lL of NaOH 6 mol + 1.2 mol
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and
dilution with provided diluent buffer (200 lL) to produce
a final 1:4 dilution. Recombinant myostatin was used as a
standard (33.3–2000 pg/mL). Concentrations of serum
follistatin (DFN00; R&D Systems, Abingdon, UK) and
serum GDF11 (DY1958; R&D Systems) were quantified
by ELISA, per manufacturer’s instructions. Recombinant
follistatin (250–16,000 pg/mL) and GDF11 (15.6–
1000 pg/mL) were as standards. Plates were read spec-
trophotometrically at 450 nm and blanked to 570 nm
(VersaMax; Molecular Devices, CA). Coefficient of vari-
ability of standards and samples were 7% and 6%, 6%
and 4%, and 4% and 8%, for myostatin follistatin, and
GDF11, respectively.
Body composition and performance
measures
Height was measured to the nearest 0.1 cm using a sta-
diometer (Seca, Birmingham, UK), and a multifrequency
bioelectrical impedance analyzer (BIA; Tanita MC-180MA
Body Composition Analyzer, Tanita, Chicago, IL) was
used to determine body mass and body composition as
described elsewhere (Hayes et al. 2013b). Participant peak
power output was assessed using the Herbert 6-sec cycle
test (Herbert et al. 2015b) and participants’ individual
values were used to calculate the resistance (40% peak
power output) during HIIT. VO2peak was determined by
indirect calorimetry as previously described (Knowles
et al. 2015).
Exercise training
HIIT sessions were performed once every 5 days for
6 weeks (nine sessions in total) as previously described
(Knowles et al. 2015; Hayes et al. 2017; Herbert et al.
2017). Rationale for this program is provided by our previ-
ous work which identified that 5 days of recovery was
required for recovery of peak power output in aging men
(Herbert et al. 2015a). Each session consisted of 6 9 30 sec
sprints at 40% predefined peak power output interspersed
with 3 min active recovery on a cycle ergometer (Wattbike
Ltd., Nottingham, UK). Sessions were conducted in groups
of between four and six participants and were the sole exer-
cise performed by both groups during this time.
Statistical analysis
Following confirmation of parametricity by a Shapiro–
Wilk test of normality and Levene’s test for homogeneity
of variance, a mixed (between group [SED,
LEX] 9 within individual time [pre-HIIT and post-
HIIT]) repeated measures analysis of variance (ANOVA)
Table 1. Participant anthropometric and performance parameters
on enrollment to the investigation in lifelong SED, and LEX, older
males.
SED (n = 13) LEX (n = 11)
Age, years 64 (6) 62 (6)
Stature, cm 174 (6) 174 (6)
Body mass, kg 91 (19) 80 (12)
Body fat, % 24 (16) 16 (6)
FFM, kg 66 (6) 66 (7)
Peak oxygen uptake, mL/kg per min 28 (6) 40 (7)1
Peak power output, W 663 (147) 831 (221)1
Peak power output, W/kg FFM 10 (2) 12 (2)1
Data presented as mean (SD). FFM, fat-free mass; SED, sedentary;
LEX, lifelong exercising.
1
Denotes significantly different than SED (P < 0.05).
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was used for differences in groups and time points with
Bonferroni post-hoc. Nonparametric data were examined
by Fishers exact test, with correction for multiple compar-
isons by Bonferroni’s method. Alpha level was set a priori
at P < 0.05, and effect size for paired comparisons is
reported as Cohen’s d throughout, interpreted as trivial
(<0.2), small (≥0.2), moderate (≥0.5), and large (≥0.8).
Parametric datasets are summarized in text as mean (SD),
while nonparametric are given as median (upper  lower
quartile). Figures are presented as grouped dot plots, as
recommended by Drummond and Vowler (2012).
Results
Pre-HIIT, SED individuals were heavier (P = 0.131,
Cohen’s d = 0.66) with a greater body fat percentage
(P = 0.120, Cohen’s d = 0.66) than LEX. SED had a
lower VO2peak (P < 0.001, Cohen’s d = 2.00), absolute
peak power output (P = 0.036, Cohen’s d = 0.90), and
relative peak power output (a surrogate for muscle qual-
ity; P = 0.020, Cohen’s d = 1.08) than LEX (Table 1).
There was no group 9 time interaction for total myo-
statin protein (P = 0.750), nor was there an effect of
group (P = 0.081) or time (P = 0.701). However, large
effect sizes were noted between SED and LEX total myo-
statin both pre-HITT (4217 [317] pg/mL and 3394 [391]
pg/mL in SED and LEX, respectively; Cohen’s d = 2.06;
Fig. 1A) and post-HIIT (4163 [337] pg/mL and 3678
[438] pg/mL in SED and LEX, respectively; Cohen’s
d = 1.24). Following HIIT, SED experienced only trivial
increases in total myostatin (Cohen’s d = 0.17) while LEX
moderately increased total myostatin (Cohen’s d = 0.68).
In a similar manner to total myostatin, there was no
group 9 time interaction for free myostatin protein
(P = 0.790), nor and effect of group (0.996) or time
(P = 0.601). No notable effect size changes were observed
for free myostatin pre-HIIT (1182.0 [372.2] pg/mL and
1159.3 [418.1] pg/mL in SED and LEX, respectively;
Cohen’s d = 0.06; Fig. 1B) or post-HITT (1203.3 [533.3]
pg/mL and 1224.5 [404.1] pg/mL in SED and LEX, respec-
tively; Cohen’s d = 0.05). Moreover, neither SED (Cohen’s
d = 0.05) nor LEX (Cohen’s d = 0.16) had any more than
a trivial effect on free myostatin from pre- to post-HIIT.
There was a significant main effect of group
(P = 0.002), but not time (P = 0.171), or a group 9 time
interaction (P = 0.561) for serum follistatin. SED follis-
tatin was greater than LEX follistatin pre-HIIT (2508
[628] pg/mL and 2102 [598] pg/mL in SED and LEX,
respectively; P = 0.132, Cohen’s d = 0.66). SED follistatin
was also greater than LEX follistatin post-HIIT (3043
[676] pg/mL and 2126 [809] pg/mL in SED and LEX,
respectively; P < 0.001, Cohen’s d = 1.22). The HIIT-
induced increase in follistatin was large in SED
(P = 0.011, Cohen’s d = 0.82), while LEX experienced no
change (P = 0.443, Cohen’s d = 0.03).
GDF11 data were examined by Fishers exact test, and
presented as median (upper  lower quartile). GDF11
was higher in LEX pre-HIIT (P = 0.012, Cohen’s
d = 0.49), and post-HIIT (P = 0.009, Cohen’s d = 0.63)
compared to SED. HIIT resulted in no change to GDF11
Figure 1. Effect of HIIT on growth factor family members in SED (N = 13) and LEX (N = 11) individuals. Concentration of (A) total myostatin,
(B) free myostatin, (C) follistatin and (D) GDF11 pre- and post-HIIT. Note (D) is expressed on a logarithmic y axis. HIIT, high-intensity interval
training; LEX, lifelong exercising; SED, sedentary; GDF11, growth and differentiation factor 11.
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in SED (70.7 [52.6–193.1], 77.1 [73.1–104.3] pg/mL pre-
and post-HIIT, respectively; P = 0.74, Cohen’s d = 0.03)
or LEX (272.7 [219.2–387.2], 305.0 [243.8–399.4] pg/mL
pre- and post-HIIT, respectively; P = 0.72, Cohen’s
d = 0.00).
As we have previously reported in a larger cohort
(Hayes et al. 2013a), peak power output was higher in
LEX individuals relative to SED (P = 0.036, Fig. 2A).
There was no correlation between peak power output and
total myostatin (P = 0.196, r = 0.273), free myostatin
(P = 0.812, r = 0.051), or follistatin (P = 0.569,
r = 0.113). However, strong positive correlations were
observed between GDF11 and both absolute peak power
output (P = 0.002, r = 0.603; Fig. 2B) and relative peak
power output (P < 0.001, r = 0.636; Fig. 2C).
Discussion
The main finding of this preliminary study was that SED
presented greater concentrations of serum total myostatin
and follistatin, and lower concentrations of GDF11, com-
pared with LEX pre-HIIT. Serum follistatin alone
responded significantly to HIIT but was confined to the
SED group. A notable and novel finding from this study
is the observed association between peak power output
and GDF11, which has not been previously demonstrated
in the human. These data provide preliminary evidence
that the role of GDF11 in healthy aging observed in mice
is maintained in humans.
With regard to healthy aging, our finding that LEX dis-
played significantly higher GDF11 than SED at baseline is
novel and noteworthy. It has been noted that older mice
treated with plasma from younger mice show a younger
phenotype (Horrington et al. 1960; Lunsford et al. 1963),
which has since been partially attributed to GDF11 differ-
ences in older and younger mice. In mice, midlife GDF11
is predictive of longevity (Zhou et al. 2016). Aged mice
show a typical “older muscle” phenotype which results in
lower muscle volume, endurance, and grip strength rela-
tive to young mice. Moreover, treatment with recombi-
nant GDF11 returned grip strength to near young levels,
and improved running endurance performance (Sinha
et al. 2014). However, it has also been noted that GDF11
may inhibit myoblast differentiation into mature myo-
tubes in a myostatin-like manner (Egerman et al. 2015),
perhaps unsurprising, as the myostatin and GDF11 pep-
tide share ~90% homogeneity. It should be further
noted that Egerman et al. (2015) used in vitro doses of
10–100 ng/mL, while both their data, and our data
reported here, suggests circulating GDF11 in older males
is 100–1000 pg/mL, an order of magnitude lower in con-
centration, possibly explaining the disparity of these find-
ings.
This argument that GDF11 concentration plays a role
in successful aging is supported by two separate findings
we report here. First, we note GDF11 is significantly
higher in LEX than SED, with some overlap between
Figure 2. Correlations between myostatin-interacting factors and
peak power output (W). (A) Peak power output (W) by group (SED,
LEX). Horizontal solid lines indicate group mean. (B) GDF11 (pg/mL)
as a function of peak power output (W). (C) GDF11 (pg/mL) as a
function of peak power output (W/kg FFM). Dashed line indicates
95% confidence intervals. Closed circles are SED (N = 13), open
squares are LEX (N = 11). LEX, lifelong exercising; SED, sedentary;
GDF11, growth and differentiation factor 11.
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these groups. Further, we note a significant moderate pos-
itive correlation between peak power output (both abso-
lute power and relative to FFM) and GDF11, independent
of grouping. While our data does not allow us to suggest
causality, it is exciting to note this correlative relation-
ship. To the best of our knowledge, this is the first dataset
linking successful aging and improved muscle function in
the human with GDF11, and directly links our findings
with those of Sinha et al. (2014), that exogenous GDF11
protects older mice against aging- and sedentarism-asso-
ciated frailty. It is thus tempting to suggest GDF11 plays
a similar role in aging humans, and this hypothesis needs
to be further explored with experimental approaches to
increase GDF11 expression in humans.
Circulating myostatin is noted to correlate with lean
muscle mass across both healthy and cachexic individuals
(Gonzalez-Cadavid et al. 1998). As SED and LEX pre-
sented with different body composition at baseline, the
moderately lower concentrations of total myostatin in
LEX at baseline is understandable. While others have
reported decreases in plasma myostatin and gains in mus-
cle mass following resistance exercise (Walker et al. 2004;
Saremi et al. 2010), limited research regarding interaction
between HIIT and myostatin exists. Pugh et al. (2015)
reported reduced muscular myostatin mRNA in healthy
individuals 2 and 6 h following a single bout of HIIT
(although a different protocol to that employed herein),
yet we are the first group to report chronic changes to
resting serum myostatin following HIIT. The aim of HIIT
is not primarily to build muscle mass, so while our HIIT
protocol did not significantly alter serum total or free
myostatin, expectations of an alteration in this peptide
may have been ambitious in the absence of muscle mass
alteration.
While our findings concerning GDF11 are noteworthy,
we acknowledge certain limitations of the present investi-
gation. While we attribute differences in GDF11 to life-
long activity differences, we acknowledge that we cannot
separate how much exercise was required to produce
these observed differences. The addition of a moderately
active group (meeting physical activity guidelines), would
allow for comparison of multiple exercise habits, rather
than the two extremes presented here. Moreover, our lack
of inactive control group (no HIIT) and relatively small
sample size may limit interpretations. The present investi-
gation formed part of a larger research study with other
primary outcome variables (Grace et al. 2015; Knowles
et al. 2015; Herbert et al. 2017), and therefore only a sub-
set of participants were analyzed. As such, our results
remain preliminary until the influence of exercise habits
on serum GDF11 is investigated with either a large-scale
randomized control trial (RCT) or prospective observa-
tional trial.
To date, much attention has been placed on myostatin
itself, with alterations in myostatin expression resulting in
significant and striking alterations in muscle mass in ani-
mal models (Kambadur et al. 1997; Mosher et al. 2007).
However, here, we show that total myostatin only moder-
ately differs in a model of successful aging, suggesting the
role of myostatin may not be as important in successful
aging as other factors reported here. Instead, greater focus
may need to be placed on these myostatin-interacting fac-
tors, as we showed follistatin was lower, and GDF11 was
higher in our LEX model of successful aging. Further, the
correlation between GDF11 and muscle quality is exciting,
and may suggest a protective role of GDF11 against




Amthor, H., G. Nicholas, I. McKinnell, C. F. Kemp, M.
Sharma, R. Kambadur, et al. 2004. Follistatin complexes
Myostatin and antagonises Myostatin-mediated inhibition of
myogenesis. Dev. Biol. 270:19–30.
Bell, K. E., C. Seguin, G. Parise, S. K. Baker, and S. M.
Phillips. 2015. Day-to-day changes in muscle protein
synthesis in recovery from resistance, aerobic, and high-
intensity interval exercise in older men. J. Gerontol. A Biol.
Sci. Med. Sci. 70:1024–1029.
Bowling, A., and P. Dieppe. 2005. What is successful ageing
and who should define it? BMJ 331:1548–1551.
Cassidy, S., C. Thoma, K. Hallsworth, J. Parikh, K. G.
Hollingsworth, R. Taylor, et al. 2016. High intensity
intermittent exercise improves cardiac structure and
function and reduces liver fat in patients with type 2
diabetes: a randomised controlled trial. Diabetologia
59:56–66.
Drummond, G. B., and S. L. Vowler. 2012. Do as you would
be done by: write as you would wish to read. J. Physiol.
590:6251–6254.
Egerman, M. A., S. M. Cadena, J. A. Gilbert, A. Meyer, H. N.
Nelson, S. E. Swalley, et al. 2015. GDF11 increases with age
and inhibits skeletal muscle regeneration. Cell Metab.
22:164–174.
Elliott, B., D. Renshaw, S. Getting, and R. Mackenzie. 2012.
The central role of myostatin in skeletal muscle and whole
body homeostasis. Acta Physiol. (Oxf) 205:324–340.
Elliott, B., Z. Shinwari, Z. Altayar, L. Barrios, G. Chaudhary,
E. Hanifa, et al. 2016. Circulating myostatin is reduced with
aging in humans but not altered by short-term, high
intensity training. Proc. Physiol. Soc. 37.
Gilson, H., O. Schakman, S. Kalista, P. Lause, K. Tsuchida,
and J. P. Thissen. 2009. Follistatin induces muscle
2017 | Vol. 5 | Iss. 13 | e13343
Page 6
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
GDF11 is Increased in Successful Aging B. T. Elliott et al.
hypertrophy through satellite cell proliferation and
inhibition of both myostatin and activin. Am. J. Physiol.
Endocrinol. Metab. 297:E157–E164.
Gonzalez-Cadavid, N. F., W. E. Taylor, K. Yarasheski, I. Sinha-
Hikim, K. Ma, S. Ezzat, et al. 1998. Organization of the
human myostatin gene and expression in healthy men and
HIV-infected men with muscle wasting. Proc. Natl Acad.
Sci. USA 95:14938–14943.
Grace, F. M., P. Herbert, J. W. Ratcliffe, K. J. New, J. S. Baker,
and N. F. Sculthorpe. 2015. Age related vascular endothelial
function following lifelong sedentariness: positive impact of
cardiovascular conditioning without further improvement
following low frequency high intensity interval training.
Physiol Rep 3:pii: e12234.
Hayes, L. D., F. M. Grace, N. Sculthorpe, P. Herbert, L. P.
Kilduff, and J. S. Baker. 2013a. Does chronic exercise
attenuate age-related physiological decline in males? Res.
Sports Med. 21:343–354.
Hayes, L. D., F. M. Grace, N. Sculthorpe, P. Herbert, J. W.
Ratcliffe, L. P. Kilduff, et al. 2013b. The effects of a formal
exercise training programme on salivary hormone
concentrations and body composition in previously
sedentary aging men. Springerplus 2:18.
Hayes, L., P. Herbert, N. Sculthorpe, and F. Grace. 2017.
Exercise training improves free testosterone in lifelong
sedentary aging men. Endocr. Connect. pii: EC-17-0082.
Herbert, P., F. M. Grace, and N. F. Sculthorpe. 2015a.
Exercising caution: prolonged recovery from a single session
of high-intensity interval training in older men. J. Am.
Geriatr. Soc. 63:817–818.
Herbert, P., N. Sculthorpe, J. S. Baker, and F. M. Grace.
2015b. Validation of a six-second cycle test for the
determination of peak power output. Res. Sports Med.
23:115–125.
Herbert, P., L. D. Hayes, N. Sculthorpe, and F. M. Grace.
2017. High-intensity interval training (HIIT) increases
insulin-like growth factor-I (IGF-I) in sedentary aging men
but not masters’ athletes: an observational study. Aging
Male 20:54–59.
Hill, J. J., M. V. Davies, A. A. Pearson, J. H. Wang, R. M.
Hewick, N. M. Wolfman, et al. 2002. The myostatin
propeptide and the follistatin-related gene are inhibitory
binding proteins of myostatin in normal serum. J. Biol.
Chem. 277:40735–40741.
Horrington, E. M., F. Pope, W. Lunsford, and C. C. Mc. 1960.
Age changes in the bones, blood pressure, and diseases of
rats in parabiosis. Gerontologia 4:21–31.
Kambadur, R., M. Sharma, T. P. Smith, and J. J. Bass. 1997.
Mutations in myostatin (GDF8) in double-muscled Belgian
Blue and Piedmontese cattle. Genome Res. 7:910–916.
Knowles, A. M., P. Herbert, C. Easton, N. Sculthorpe, and F.
M. Grace. 2015. Impact of low-volume, high-intensity
interval training on maximal aerobic capacity, health-related
quality of life and motivation to exercise in ageing men. Age
(Dordr.) 37:25.
Lee, S. J., and A. C. McPherron. 1999. Myostatin and the
control of skeletal muscle mass. Curr. Opin. Genet. Dev.
9:604–607.
Lunsford, W. R., C. C. Mc, P. J. Lupien, F. E. Pope, and G.
Sperling. 1963. Parabiosis as a method for studying factors
which affect aging in rats. Gerontologia 7:1–8.
Metter, E. J., L. A. Talbot, M. Schrager, and R. Conwit. 2002.
Skeletal muscle strength as a predictor of all-cause mortality
in healthy men. J. Gerontol. A Biol. Sci. Med. Sci. 57:B359–
B365.
Mosher, D. S., P. Quignon, C. D. Bustamante, N. B. Sutter, C.
S. Mellersh, H. G. Parker, et al. 2007. A mutation in the
myostatin gene increases muscle mass and enhances racing
performance in heterozygote dogs. PLoS Genet. 3:e79.
Pollock, R. D., S. Carter, C. P. Velloso, N. A. Duggal, J. M. Lord,
N. R. Lazarus, et al. 2015. An investigation into the
relationship between age and physiological function in highly
active older adults. J. Physiol., 593:657–680; discussion 680.
Pugh, J. K., S. H. Faulkner, A. P. Jackson, J. A. King, and M.
A. Nimmo. 2015. Acute molecular responses to concurrent
resistance and high-intensity interval exercise in untrained
skeletal muscle. Physiol. Rep. 3:pii: e12364.
Ramos, J. S., L. C. Dalleck, A. E. Tjonna, K. S. Beetham, and J.
S. Coombes. 2015. The impact of high-intensity interval
training versus moderate-intensity continuous training on
vascular function: a systematic review and meta-analysis.
Sports Med. 45:679–692.
Ratkevicius, A., A. Joyson, I. Selmer, T. Dhanani, C. Grierson,
A. M. Tommasi, et al. 2011. Serum concentrations of
myostatin and myostatin-interacting proteins do not differ
between young and sarcopenic elderly men. J. Gerontol. A
Biol. Sci. Med. Sci. 66:620–626.
Roth, S. M., G. F. Martel, R. E. Ferrell, E. J. Metter, B. F.
Hurley, and M. A. Rogers. 2003. Myostatin gene expression
is reduced in humans with heavy-resistance strength
training: a brief communication. Exp. Biol. Med.
(Maywood) 228:706–709.
Rowe, J. W., and R. L. Kahn. 1987. Human aging: usual and
successful. Science 237:143–149.
Saremi, A., R. Gharakhanloo, S. Sharghi, M. R. Gharaati, B.
Larijani, and K. Omidfar. 2010. Effects of oral creatine and
resistance training on serum myostatin and GASP-1. Mol.
Cell. Endocrinol. 317:25–30.
Sculthorpe, N. F., P. Herbert, and F. Grace. 2017. One session
of high-intensity interval training (HIIT) every 5 days,
improves muscle power but not static balance in lifelong
sedentary ageing men: a randomized controlled trial.
Medicine (Baltimore) 96:e6040.
Shiraev, T., and G. Barclay. 2012. Evidence based exercise -
clinical benefits of high intensity interval training. Aust.
Fam. Physician 41:960–962.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2017 | Vol. 5 | Iss. 13 | e13343
Page 7
B. T. Elliott et al. GDF11 is Increased in Successful Aging
Sinha, M., Y. C. Jang, J. Oh, D. Khong, E. Y. Wu, R.
Manohar, et al. 2014. Restoring systemic GDF11 levels
reverses age-related dysfunction in mouse skeletal muscle.
Science 344:649–652.
Thum, J. S., G. Parsons, T. Whittle, and T. A. Astorino. 2017.
High-intensity interval training elicits higher enjoyment
than moderate intensity continuous exercise. PLoS ONE 12:
e0166299.
Walker, K. S., R. Kambadur, M. Sharma, and H. K. Smith.
2004. Resistance training alters plasma myostatin but
not IGF-1 in healthy men. Med. Sci. Sports Exerc.
36:787–793.
Walker, R. G., T. Poggioli, L. Katsimpardi, S. M. Buchanan, J.
Oh, S. Wattrus, et al. 2016. Biochemistry and biology of
GDF11 and myostatin: similarities, differences, and
questions for future investigation. Circ. Res. 118:1125–1141;
discussion 1142.
Whittemore, L. A., K. Song, X. Li, J. Aghajanian, M. Davies, S.
Girgenrath, et al. 2003. Inhibition of myostatin in adult
mice increases skeletal muscle mass and strength. Biochem.
Biophys. Res. Commun. 300:965–971.
Yarasheski, K. E., S. Bhasin, I. Sinha-Hikim, J. Pak-Loduca,
and N. F. Gonzalez-Cadavid. 2002. Serum myostatin-
immunoreactive protein is increased in 60-92 year old
women and men with muscle wasting. J. Nutr. Health Aging
6:343–348.
Zhou, Y., Z. Jiang, E. C. Harris, J. Reeves, X. Chen, and R.
Pazdro. 2016. Circulating concentrations of growth
differentiation factor 11 are heritable and correlate with life
span. J. Gerontol. A Biol. Sci. Med. Sci. 71:1560–1563.
Zimmers, T. A., M. V. Davies, L. G. Koniaris, P. Haynes, A. F.
Esquela, K. N. Tomkinson, et al. 2002. Induction of
cachexia in mice by systemically administered myostatin.
Science 296:1486–1488.
2017 | Vol. 5 | Iss. 13 | e13343
Page 8
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
GDF11 is Increased in Successful Aging B. T. Elliott et al.
